Children with leukemia were one of the original target groups for the vaccine. After investigational trials in normal children and adults, the vaccine was administered to leukemic children who were no longer receiving chemotherapy and, subsequently, to children who had been in remission for year but still required maintenance chemotherapy. In these subjects, the vaccine has been highly immunogenic, producing seroconversion in 90% and 97% of patients after 1 and 2 doses, respectively. ' 
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